Pseudomonas aeruginosa
Pseudomonas
Pseudomonas putida
Pseudomonas fluorescens
Cystic Fibrosis
Pseudomonas Phages
Alginates
ADP Ribose Transferases
Microbial Sensitivity Tests
Biofilms
Gene Expression Regulation, Bacterial
Tobramycin
Quorum Sensing
Pyocins
Glucuronic Acid
Carbenicillin
Virulence Factors
Molecular Sequence Data
Exotoxins
Ceftazidime
Imipenem
Gram-Negative Bacteria
Pseudomonas syringae
4-Butyrolactone
Drug Resistance, Microbial
beta-Lactamases
Gentamicins
Eye Infections, Bacterial
Mutation
Hexuronic Acids
Bacteria
Bacterial Outer Membrane Proteins
Thienamycins
Bacterial Toxins
Culture Media
Carbapenems
Drug Resistance, Bacterial
Amino Acid Sequence
Pancreatic Elastase
Colistin
Azurin
Drug Resistance, Multiple, Bacterial
Pseudomonas stutzeri
Virulence
Amikacin
Aminoglycosides
Colony Count, Microbial
Bacterial Adhesion
Corneal Ulcer
Aztreonam
Anti-Infective Agents
Base Sequence
Plasmids
Sputum
Escherichia coli
Cephalosporins
Polymyxins
Cloning, Molecular
Operon
Piperacillin
Siderophores
Hydrogen Cyanide
Genetic Complementation Test
Enterobacteriaceae
Fimbriae, Bacterial
Fimbriae Proteins
Sequence Analysis, DNA
Kanamycin
Lipopolysaccharides
Burns
Porins
beta-Lactams
Quinolones
Gram-Negative Bacterial Infections
Burkholderia cepacia
Conjugation, Genetic
Staphylococcus aureus
Flagellin
Mutagenesis, Insertional
Lung
Microbial Viability
DNA Transposable Elements
Species Specificity
Polymyxin B
Penicillins
Sigma Factor
Carbohydrate Dehydrogenases
Biodegradation, Environmental
beta-Lactam Resistance
Glycolipids
Oxygenases
Sequence Homology, Amino Acid
Phenotype
O Antigens
Penicillanic Acid
Acinetobacter
Lactams
Membrane Transport Proteins
Chromosomes, Bacterial
Iron
Bacteremia
Gene Deletion
Phosphotransferases (Phosphomutases)
Alkanes
Restriction Mapping
Norfloxacin
Antibiosis
Equipment Contamination
Cefsulodin
Flagella
Integrons
RNA, Bacterial
R Factors
Anaerobiosis
Ofloxacin
Electrophoresis, Gel, Pulsed-Field
Klebsiella pneumoniae
Bronchopneumonia
Mannose-6-Phosphate Isomerase
Substrate Specificity
Disinfectants
Electrophoresis, Polyacrylamide Gel
Respiratory Tract Infections
Dioxygenases
Monobactams
Sepsis
Pseudomonas mendocina
Agar
Phagocytosis
Catechol 2,3-Dioxygenase
Rhamnose
Soil Microbiology
Periplasm
Hydrogen-Ion Concentration
Serotyping
Cefoperazone
Multigene Family
Trans-Activators
Nitrite Reductases
4-Quinolones
Neutrophils
Acinetobacter baumannii
Transcription, Genetic
Chromobacterium
Otitis Externa
Bacteriocins
Blood Bactericidal Activity
Oxidoreductases
Plankton
Peptide Hydrolases
Polymerase Chain Reaction
Temperature
Antimicrobial Cationic Peptides
Epithelial Cells
Models, Molecular
Genes, Regulator
UK-18892, a new aminoglycoside: an in vitro study. (1/9595)
UK-18892 is a new aminoglycoside antibiotic, a derivative of kanamycin A structurally related to amikacin. It was found to be active against a wide range of pathogenic bacteria, including many gentamicin-resistant strains. The spectrum and degree of activity of UK-18892 were similar to those of amikacin, and differences were relatively minor. UK-18892 was about twice as active as amikacin against gentamicin-susceptible strains of Pseudomonas aeruginosa. Both amikacin and UK-18892 were equally active against gentamicin-resistant strains of P. aeruginosa. There were no appreciable differences in the activity of UK-18892 and amikacin against Enterobacteriaceae and Staphylococcus aureus. Cross-resistance between these two antimicrobials was also apparent. (+info)Modified peptidoglycan transpeptidase activity in a carbenicillin-resistant mutant of Pseudomonas aeruginosa 18s. (2/9595)
A carbenicillin-resistant mutant of Pseudomonas aeruginosa 18s was found to possess peptidoglycan transpeptidase activity significantly more resistant to inhibition by benzyl penicillin, ampicillin, carbenicillin, and cephaloridine than that of the parent strain. The mutant was more resistant than the parent strain to all of the beta-lactam antibiotics tested, and 50% inhibition values for these compounds against membrane-bound model transpeptidase activity paralleled this increase. The resistance of the mutant to kanamycin, streptomycin, and chloramphenicol was unchanged. (+info)Improved medium for recovery and enumeration of Pseudomonas aeruginosa from water using membrane filters. (3/9595)
A modified mPA medium, designated mPA-C, was shown to recover Pseudomonas aeruginosa from a variety of water sources with results comparable to those with mPA-B and within the confidence limits of a most-probable-number technique. Enumeration of P. aeruginosa on mPA-C was possible after only 24 h of incubation at 41.5 degrees C, compared with 72 h of incubation required for mPA-B and 96 h of incubation for a presumptive most probable number. (+info)Automated food microbiology: potential for the hydrophobic grid-membrane filter. (4/9595)
Bacterial counts obtained on hydrophobic grid-membrane filters were comparable to conventional plate counts for Pseudomonas aeruginosa, Escherichia coli, and Staphylococcus aureus in homogenates from a range of foods. The wide numerical operating range of the hydrophobic grid-membrane filters allowed sequential diluting to be reduced or even eliminated, making them attractive as components in automated systems of analysis. Food debris could be rinsed completely from the unincubated hydrophobic grid-membrane filter surface without affecting the subsequent count, thus eliminating the possibility of counting food particles, a common source of error in electronic counting systems. (+info)Denitrifying Pseudomonas aeruginosa: some parameters of growth and active transport. (5/9595)
Optimal cell yield of Pseudomonas aeruginosa grown under denitrifying conditions was obtained with 100 mM nitrate as the terminal electron acceptor, irrespective of the medium used. Nitrite as the terminal electron acceptor supported poor denitrifying growth when concentrations of less than 15 mM, but not higher, were used, apparently owing to toxicity exerted by nitrite. Nitrite accumulated in the medium during early exponential phase when nitrate was the terminal electron acceptor and then decreased to extinction before midexponential phase. The maximal rate of glucose and gluconate transport was supported by 1 mM nitrate or nitrite as the terminal electron acceptor under anaerobic conditions. The transport rate was greater with nitrate than with nitrite as the terminal electron acceptor, but the greatest transport rate was observed under aerobic conditions with oxygen as the terminal electron acceptor. When P. aeruginosa was inoculated into a denitrifying environment, nitrate reductase was detected after 3 h of incubation, nitrite reductase was detected after another 4 h of incubation, and maximal nitrate and nitrite reductase activities peaked together during midexponential phase. The latter coincided with maximal glucose transport activity. (+info)The Pseudomonas aeruginosa secretory product pyocyanin inactivates alpha1 protease inhibitor: implications for the pathogenesis of cystic fibrosis lung disease. (6/9595)
Alpha1 Protease inhibitor (alpha1PI) modulates serine protease activity in the lung. Reactive oxygen species inactivate alpha1PI, and this process has been implicated in the pathogenesis of a variety of forms of lung injury. An imbalance of protease-antiprotease activity is also detected in the airways of patients with cystic fibrosis-associated lung disease who are infected with Pseudomonas aeruginosa. P. aeruginosa secretes pyocyanin, which, through its ability to redox cycle, induces cells to generate reactive oxygen species. We tested the hypothesis that redox cycling of pyocyanin could lead to inactivation of alpha1PI. When alpha1PI was exposed to NADH and pyocyanin, a combination that results in superoxide production, alpha1PI lost its ability to form an inhibitory complex with both porcine pancreatic elastase (PPE) and trypsin. Similarly, addition of pyocyanin to cultures of human airway epithelial cells to which alpha1PI was also added resulted in a loss of the ability of alpha1PI to form a complex with PPE or trypsin. Neither superoxide dismutase, catalase, nor dimethylthiourea nor depletion of the media of O2 to prevent formation of reactive oxygen species blocked pyocyanin-mediated inactivation of alpha1PI. These data raise the possibility that a direct interaction between reduced pyocyanin and alpha1PI is involved in the process. Consistent with this possibility, pretreatment of alpha1PI with the reducing agent beta-mercaptoethanol also inhibited binding of trypsin to alpha1PI. These data suggest that pyocyanin could contribute to lung injury in the P. aeruginosa-infected airway of cystic fibrosis patients by decreasing the ability of alpha1PI to control the local activity of serine proteases. (+info)Safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein F-I vaccine in human volunteers. (7/9595)
A hybrid protein [Met-Ala-(His)6OprF190-342-OprI21-83] consisting of the mature outer membrane protein I (OprI) and amino acids 190 to 342 of OprF of Pseudomonas aeruginosa was expressed in Escherichia coli and purified by Ni2+ chelate-affinity chromatography. After safety and pyrogenicity evaluations in animals, four groups of eight adult human volunteers were vaccinated intramuscularly three times at 4-week intervals and revaccinated 6 months later with either 500, 100, 50, or 20 microg of OprF-OprI adsorbed onto A1(OH)3. All vaccinations were well tolerated. After the first vaccination, a significant rise of antibody titers against P. aeruginosa OprF and OprI was measured in volunteers receiving the 100- or the 500-microg dose. After the second vaccination, significant antibody titers were measured for all groups. Elevated antibody titers against OprF and OprI could still be measured 6 months after the third vaccination. The capacity of the elicited antibodies to promote complement binding and opsonization could be demonstrated by a C1q-binding assay and by the in vitro opsonophagocytic uptake of P. aeruginosa bacteria. These data support the continued development of an OprF-OprI vaccine for use in humans. (+info)Lipopolysaccharide (LPS) from Burkholderia cepacia is more active than LPS from Pseudomonas aeruginosa and Stenotrophomonas maltophilia in stimulating tumor necrosis factor alpha from human monocytes. (8/9595)
Whole cells and lipopolysaccharides (LPSs) extracted from Burkholderia cepacia, Pseudomonas aeruginosa, Stenotrophomonas maltophilia, and Escherichia coli were compared in their ability to stimulate tumor necrosis factor alpha (TNF-alpha) from the human monocyte cell line MonoMac-6. B. cepacia LPS, on a weight-for-weight basis, was found to have TNF-alpha-inducing activity similar to that of LPS from E. coli, which was approximately four- and eightfold greater than the activity of LPSs from P. aeruginosa and S. maltophilia, respectively. The LPS-stimulated TNF-alpha production from monocytes was found to be CD14 dependent. These results suggest that B. cepacia LPS might play a role in the pathogenesis of inflammatory lung disease in cystic fibrosis, and in some patients it might be responsible, at least in part, for the sepsis-like cepacia syndrome. (+info)Pseudomonas infections are challenging to treat due to the bacteria's ability to develop resistance against antibiotics. The treatment typically involves a combination of antibiotics and other supportive therapies, such as oxygen therapy or mechanical ventilation, to manage symptoms and prevent complications. In some cases, surgical intervention may be necessary to remove infected tissue or repair damaged organs.
Symptoms of cystic fibrosis can vary from person to person, but may include:
* Persistent coughing and wheezing
* Thick, sticky mucus that clogs airways and can lead to respiratory infections
* Difficulty gaining weight or growing at the expected rate
* Intestinal blockages or digestive problems
* Fatty stools
* Nausea and vomiting
* Diarrhea
* Rectal prolapse
* Increased risk of liver disease and respiratory failure
Cystic fibrosis is usually diagnosed in infancy, and treatment typically includes a combination of medications, respiratory therapy, and other supportive care. Management of the disease focuses on controlling symptoms, preventing complications, and improving quality of life. With proper treatment and care, many people with cystic fibrosis can lead long, fulfilling lives.
In summary, cystic fibrosis is a genetic disorder that affects the respiratory, digestive, and reproductive systems, causing thick and sticky mucus to build up in these organs, leading to serious health problems. It can be diagnosed in infancy and managed with a combination of medications, respiratory therapy, and other supportive care.
1. Conjunctivitis: This is an infection of the conjunctiva, which is the thin membrane that covers the white part of the eye and the inside of the eyelids. It is often caused by Streptococcus pneumoniae or Haemophilus influenzae bacteria.
2. Corneal ulcers: These are open sores that develop on the surface of the cornea, which is the clear dome-shaped surface at the front of the eye. Corneal ulcers can be caused by a variety of bacteria, including Staphylococcus aureus and Streptococcus pyogenes.
3. Endophthalmitis: This is an infection that occurs inside the eye, often as a complication of cataract surgery or other types of ocular surgery. It can be caused by a variety of bacteria, including Staphylococcus aureus and Streptococcus epidermidis.
4. Keratitis: This is an infection of the cornea that can be caused by a variety of bacteria, including Pseudomonas aeruginosa and Acinetobacter baumannii.
5. Retinitis: This is an infection of the retina, which is the layer of tissue at the back of the eye that senses light and sends visual signals to the brain. Retinitis can be caused by a variety of bacteria, including Haemophilus influenzae and Streptococcus pneumoniae.
Bacterial eye infections can cause a range of symptoms, including redness, swelling, discharge, pain, and blurred vision. Treatment typically involves antibiotic eye drops or ointments, and in more severe cases, oral antibiotics may be prescribed. It is important to seek medical attention if you experience any symptoms of a bacterial eye infection, as early treatment can help prevent complications and improve outcomes.
The symptoms of a corneal ulcer may include:
* Pain or discomfort in the eye
* Redness and swelling of the eye
* Discharge or pus in the eye
* Blurred vision or sensitivity to light
* A feeling that there is something in the eye
If left untreated, a corneal ulcer can lead to complications such as:
* Perforation of the cornea
* Inflammation of the iris (iritis)
* Inflammation of the retina (retinitis)
* Vision loss or blindness
Treatment of a corneal ulcer typically involves antibiotic eye drops or ointments to treat any underlying bacterial infection, as well as supportive care to manage pain and promote healing. In severe cases, surgery may be necessary to remove the damaged tissue and promote healing.
Prevention of corneal ulcers includes good hygiene, proper use of contact lenses, and avoiding touching or rubbing the eyes. Early detection and treatment are key to preventing complications and preserving vision.
Also known as: Corneal inflammation, Eye inflammation, Keratoconjunctivitis, Ocular inflammation.
The most common bacteria that cause pneumonia are Streptococcus pneumoniae (also known as pneumococcus), Haemophilus influenzae, and Staphylococcus aureus. These bacteria can infect the lungs through various routes, including respiratory droplets, contaminated food or water, or direct contact with an infected person.
Symptoms of pneumonia may include cough, fever, chills, shortness of breath, and chest pain. In severe cases, pneumonia can lead to serious complications such as respiratory failure, sepsis, and death.
Diagnosis of pneumonia typically involves a physical examination, medical history, and diagnostic tests such as chest X-rays or blood cultures. Treatment typically involves antibiotics to eliminate the infection, as well as supportive care to manage symptoms and prevent complications. Vaccines are also available to protect against certain types of bacterial pneumonia, particularly in children and older adults.
Preventative measures for bacterial pneumonia include:
* Getting vaccinated against Streptococcus pneumoniae and Haemophilus influenzae type b (Hib)
* Practicing good hygiene, such as washing hands regularly and covering the mouth and nose when coughing or sneezing
* Avoiding close contact with people who are sick
* Staying hydrated and getting enough rest
* Quitting smoking, if applicable
* Managing underlying medical conditions, such as diabetes or heart disease
It is important to seek medical attention promptly if symptoms of pneumonia develop, particularly in high-risk populations. Early diagnosis and treatment can help prevent serious complications and improve outcomes for patients with bacterial pneumonia.
In medicine, cross-infection refers to the transmission of an infectious agent from one individual or source to another, often through direct contact or indirect exposure. This type of transmission can occur in various settings, such as hospitals, clinics, and long-term care facilities, where patients with compromised immune systems are more susceptible to infection.
Cross-infection can occur through a variety of means, including:
1. Person-to-person contact: Direct contact with an infected individual, such as touching, hugging, or shaking hands.
2. Contaminated surfaces and objects: Touching contaminated surfaces or objects that have been touched by an infected individual, such as doorknobs, furniture, or medical equipment.
3. Airborne transmission: Inhaling droplets or aerosolized particles that contain the infectious agent, such as during coughing or sneezing.
4. Contaminated food and water: Consuming food or drinks that have been handled by an infected individual or contaminated with the infectious agent.
5. Insect vectors: Mosquitoes, ticks, or other insects can transmit infections through their bites.
Cross-infection is a significant concern in healthcare settings, as it can lead to outbreaks of nosocomial infections (infections acquired in hospitals) and can spread rapidly among patients, healthcare workers, and visitors. To prevent cross-infection, healthcare providers use strict infection control measures, such as wearing personal protective equipment (PPE), thoroughly cleaning and disinfecting surfaces, and implementing isolation precautions for infected individuals.
In summary, cross-infection refers to the transmission of an infectious agent from one individual or source to another, often through direct contact or indirect exposure in healthcare settings. Preventing cross-infection is essential to maintaining a safe and healthy environment for patients, healthcare workers, and visitors.
Symptoms of wound infection may include:
* Redness, swelling, or increased pain around the wound
* Increased drainage or pus from the wound
* Bad smell or discharge from the wound
* Fever or chills
* Swollen lymph nodes
Treatment of wound infection usually involves antibiotics and may require surgical intervention to remove infected tissue. It is important to practice good wound care, such as keeping the wound clean and dry, changing dressings regularly, and monitoring for signs of infection to prevent the development of a wound infection.
Preventive measures include:
* Proper sterilization and technique during surgery or medical procedures
* Keeping the wound site clean and dry
* Removing any dead tissue or debris from the wound
* Using antibiotic ointment or cream to prevent infection
* Covering the wound with a sterile dressing
If you suspect that you have a wound infection, it is important to seek medical attention as soon as possible. A healthcare professional can evaluate the wound and provide appropriate treatment to prevent further complications.
First-degree burns are the mildest form of burn and affect only the outer layer of the skin. They are characterized by redness, swelling, and pain but do not blister or scar. Examples of first-degree burns include sunburns and minor scalds from hot liquids.
Second-degree burns are more severe and affect both the outer and inner layers of the skin. They can cause blisters, redness, swelling, and pain, and may lead to infection. Second-degree burns can be further classified into two subtypes: partial thickness burns (where the skin is damaged but not completely destroyed) and full thickness burns (where the skin is completely destroyed).
Third-degree burns are the most severe and affect all layers of the skin and underlying tissues. They can cause charring of the skin, loss of function, and may lead to infection or even death.
There are several ways to treat burns, including:
1. Cooling the burn with cool water or a cold compress to reduce heat and prevent further damage.
2. Keeping the burn clean and dry to prevent infection.
3. Applying topical creams or ointments to help soothe and heal the burn.
4. Taking pain medication to manage discomfort.
5. In severe cases, undergoing surgery to remove damaged tissue and promote healing.
Prevention is key when it comes to burns. Some ways to prevent burns include:
1. Being cautious when handling hot objects or substances.
2. Keeping a safe distance from open flames or sparks.
3. Wearing protective clothing, such as gloves and long sleeves, when working with hot materials.
4. Keeping children away from hot surfaces and substances.
5. Installing smoke detectors and fire extinguishers in the home to reduce the risk of fires.
Overall, burns can be a serious condition that requires prompt medical attention. By understanding the causes, symptoms, and treatments for burns, individuals can take steps to prevent them and seek help if they do occur.
Some common examples of bacterial infections include:
1. Urinary tract infections (UTIs)
2. Respiratory infections such as pneumonia and bronchitis
3. Skin infections such as cellulitis and abscesses
4. Bone and joint infections such as osteomyelitis
5. Infected wounds or burns
6. Sexually transmitted infections (STIs) such as chlamydia and gonorrhea
7. Food poisoning caused by bacteria such as salmonella and E. coli.
In severe cases, bacterial infections can lead to life-threatening complications such as sepsis or blood poisoning. It is important to seek medical attention if symptoms persist or worsen over time. Proper diagnosis and treatment can help prevent these complications and ensure a full recovery.
Gram-negative bacterial infections can be difficult to treat because these bacteria are resistant to many antibiotics. In addition, some gram-negative bacteria produce enzymes called beta-lactamases, which break down the penicillin ring of many antibiotics, making them ineffective against the infection.
Some common types of gram-negative bacterial infections include:
* Pneumonia
* Urinary tract infections (UTIs)
* Bloodstream infections (sepsis)
* Meningitis
* Skin and soft tissue infections
* Respiratory infections, such as bronchitis and sinusitis
Examples of gram-negative bacteria that can cause infection include:
* Escherichia coli (E. coli)
* Klebsiella pneumoniae
* Pseudomonas aeruginosa
* Acinetobacter baumannii
* Proteus mirabilis
Gram-negative bacterial infections can be diagnosed through a variety of tests, including blood cultures, urine cultures, and tissue samples. Treatment typically involves the use of broad-spectrum antibiotics, such as carbapenems or cephalosporins, which are effective against many types of gram-negative bacteria. In some cases, the infection may require hospitalization and intensive care to manage complications such as sepsis or organ failure.
Prevention of gram-negative bacterial infections includes good hand hygiene, proper use of personal protective equipment (PPE), and appropriate use of antibiotics. In healthcare settings, infection control measures such as sterilization and disinfection of equipment, and isolation precautions for patients with known gram-negative bacterial infections can help prevent the spread of these infections.
Overall, gram-negative bacterial infections are a significant public health concern, and proper diagnosis and treatment are essential to prevent complications and reduce the risk of transmission.
Bacteremia can occur when bacteria enter the bloodstream through various means, such as:
* Infected wounds or surgical sites
* Injecting drug use
* Skin infections
* Respiratory tract infections
* Urinary tract infections
* Endocarditis (infection of the heart valves)
The symptoms of bacteremia can vary depending on the type of bacteria and the severity of the infection. Some common symptoms include:
* Fever
* Chills
* Headache
* Muscle aches
* Weakness
* Confusion
* Shortness of breath
Bacteremia is diagnosed by blood cultures, which involve collecting blood samples and inserting them into a specialized container to grow the bacteria. Treatment typically involves antibiotics and supportive care, such as intravenous fluids and oxygen therapy. In severe cases, hospitalization may be necessary to monitor and treat the infection.
Prevention measures for bacteremia include:
* Practicing good hygiene, such as washing hands regularly
* Avoiding sharing personal items like toothbrushes or razors
* Properly cleaning and covering wounds
* Getting vaccinated against infections that can lead to bacteremia
* Following proper sterilization techniques during medical procedures
Overall, bacteremia is a serious condition that requires prompt medical attention to prevent complications and ensure effective treatment.
Some common types of lung diseases include:
1. Asthma: A chronic condition characterized by inflammation and narrowing of the airways, leading to wheezing, coughing, and shortness of breath.
2. Chronic Obstructive Pulmonary Disease (COPD): A progressive condition that causes chronic inflammation and damage to the airways and lungs, making it difficult to breathe.
3. Pneumonia: An infection of the lungs that can be caused by bacteria, viruses, or fungi, leading to fever, chills, coughing, and difficulty breathing.
4. Bronchiectasis: A condition where the airways are damaged and widened, leading to chronic infections and inflammation.
5. Pulmonary Fibrosis: A condition where the lungs become scarred and stiff, making it difficult to breathe.
6. Lung Cancer: A malignant tumor that develops in the lungs, often caused by smoking or exposure to carcinogens.
7. Cystic Fibrosis: A genetic disorder that affects the respiratory and digestive systems, leading to chronic infections and inflammation in the lungs.
8. Tuberculosis (TB): An infectious disease caused by Mycobacterium Tuberculosis, which primarily affects the lungs but can also affect other parts of the body.
9. Pulmonary Embolism: A blockage in one of the arteries in the lungs, often caused by a blood clot that has traveled from another part of the body.
10. Sarcoidosis: An inflammatory disease that affects various organs in the body, including the lungs, leading to the formation of granulomas and scarring.
These are just a few examples of conditions that can affect the lungs and respiratory system. It's important to note that many of these conditions can be treated with medication, therapy, or surgery, but early detection is key to successful treatment outcomes.
Bronchopneumonia is a serious condition that can lead to respiratory failure and other complications if left untreated. It is important for individuals with bronchopneumonia to seek medical attention promptly if they experience any worsening symptoms or signs of infection, such as increased fever or difficulty breathing.
Bronchopneumonia can be caused by a variety of factors, including bacterial and viral infections, and can affect individuals of all ages. It is most common in young children and the elderly, as well as those with pre-existing respiratory conditions such as asthma or chronic obstructive pulmonary disease (COPD).
Treatment for bronchopneumonia typically involves antibiotics to treat any bacterial infections, as well as supportive care to help manage symptoms and improve lung function. In severe cases, hospitalization may be necessary to provide more intensive treatment and monitoring.
In addition to antibiotics and supportive care, other treatments for bronchopneumonia may include:
* Oxygen therapy to help increase oxygen levels in the blood
* Pain management medications to relieve chest pain and fever
* Breathing exercises and pulmonary rehabilitation to improve lung function
* Rest and relaxation to help the body recover
Prevention is key in avoiding bronchopneumonia, and this can be achieved through:
* Good hand hygiene and respiratory etiquette
* Avoiding close contact with individuals who are sick
* Getting vaccinated against pneumococcal disease and the flu
* Practicing good hygiene during travel to avoid exposure to respiratory infections.
In conclusion, bronchopneumonia is a serious condition that can be caused by a variety of factors and can affect individuals of all ages. Treatment typically involves antibiotics and supportive care, and prevention strategies include good hygiene practices and vaccination. With proper treatment and care, individuals with bronchopneumonia can recover and lead active lives.
The hallmark symptoms of bronchiectasis are chronic cough, recurrent respiratory tract infections, and excessive mucus production. These symptoms can significantly impact quality of life, and if left untreated, the disease can progress to severe respiratory failure and other complications such as pulmonary hypertension.
Bronchiectasis is most commonly caused by recurrent lower respiratory tract infections, such as those caused by Pneumocystis jirovecii (formerly known as Pneumocystis carinii) and Haemophilus influenzae type b (Hib). Other risk factors for developing bronchiectasis include a history of childhood respiratory infections, exposure to tobacco smoke, and underlying conditions such as cystic fibrosis or primary immunodeficiency disorders.
Diagnosis of bronchiectasis typically involves a combination of clinical evaluation, radiologic imaging (such as high-resolution computed tomography, or HRCT), and pulmonary function tests. Treatment options for bronchiectasis include antibiotics to manage infections, bronchodilators to improve lung function, and airway clearance techniques such as chest physical therapy and pulmonary rehabilitation. In severe cases, lung transplantation may be considered.
Preventive measures for bronchiectasis include prompt treatment of respiratory infections, avoiding exposure to environmental irritants such as tobacco smoke, and managing underlying conditions that increase the risk of developing the disease. Early diagnosis and aggressive management of bronchiectasis can help slow disease progression, improve quality of life, and reduce the risk of complications such as respiratory failure and lung cancer.
The common types of RTIs include:
1. Common cold: A viral infection that affects the upper respiratory tract, causing symptoms such as runny nose, sneezing, coughing, and mild fever.
2. Influenza (flu): A viral infection that can affect both the upper and lower respiratory tract, causing symptoms such as fever, cough, sore throat, and body aches.
3. Bronchitis: An inflammation of the bronchial tubes, which can be caused by viruses or bacteria, resulting in symptoms such as coughing, wheezing, and shortness of breath.
4. Pneumonia: An infection of the lungs that can be caused by bacteria, viruses, or fungi, leading to symptoms such as fever, chills, coughing, and difficulty breathing.
5. Tonsillitis: An inflammation of the tonsils, which can be caused by bacteria or viruses, resulting in symptoms such as sore throat, difficulty swallowing, and bad breath.
6. Sinusitis: An inflammation of the sinuses, which can be caused by viruses, bacteria, or fungi, leading to symptoms such as headache, facial pain, and nasal congestion.
7. Laryngitis: An inflammation of the larynx (voice box), which can be caused by viruses or bacteria, resulting in symptoms such as hoarseness, loss of voice, and difficulty speaking.
RTIs can be diagnosed through physical examination, medical history, and diagnostic tests such as chest X-rays, blood tests, and nasal swab cultures. Treatment for RTIs depends on the underlying cause and may include antibiotics, antiviral medications, and supportive care to manage symptoms.
It's important to note that RTIs can be contagious and can spread through contact with an infected person or by touching contaminated surfaces. Therefore, it's essential to practice good hygiene, such as washing hands frequently, covering the mouth and nose when coughing or sneezing, and avoiding close contact with people who are sick.
Here are some key points to define sepsis:
1. Inflammatory response: Sepsis is characterized by an excessive and uncontrolled inflammatory response to an infection. This can lead to tissue damage and organ dysfunction.
2. Systemic symptoms: Patients with sepsis often have systemic symptoms such as fever, chills, rapid heart rate, and confusion. They may also experience nausea, vomiting, and diarrhea.
3. Organ dysfunction: Sepsis can cause dysfunction in multiple organs, including the lungs, kidneys, liver, and heart. This can lead to organ failure and death if not treated promptly.
4. Infection source: Sepsis is usually caused by a bacterial infection, but it can also be caused by fungal or viral infections. The infection can be localized or widespread, and it can affect different parts of the body.
5. Severe sepsis: Severe sepsis is a more severe form of sepsis that is characterized by severe organ dysfunction and a higher risk of death. Patients with severe sepsis may require intensive care unit (ICU) admission and mechanical ventilation.
6. Septic shock: Septic shock is a life-threatening condition that occurs when there is severe circulatory dysfunction due to sepsis. It is characterized by hypotension, vasopressor use, and organ failure.
Early recognition and treatment of sepsis are critical to preventing serious complications and improving outcomes. The Sepsis-3 definition is widely used in clinical practice to diagnose sepsis and severe sepsis.
Symptoms of otitis externa may include:
* Ear pain or tenderness
* Redness and swelling of the ear canal
* Discharge or pus in the ear canal
* Itching or burning sensation in the ear canal
* Fever or chills
* Difficulty hearing or feeling as if the ear is clogged
Otitis externa can be diagnosed by a healthcare professional through a physical examination of the ear canal and may also involve a pus sample or imaging tests such as X-rays or CT scans to rule out other conditions. Treatment options for otitis externa may include antibiotics, anti-inflammatory medications, or topical creams or drops to reduce pain and inflammation. In severe cases, surgery may be necessary to remove any infected tissue or debris from the ear canal.
Prevention of otitis externa includes avoiding exposure to moisture, using earplugs when swimming or showering, and keeping the ears clean and dry. If you suspect you have otitis externa, it is important to seek medical attention promptly to prevent complications such as mastoiditis or meningitis.
If left untreated, folliculitis can lead to more serious infections such as boils or abscesses, which may require surgical drainage. It is also possible for folliculitis to cause scarring and permanent hair loss if the inflammation damages the hair follicle.
While anyone can develop folliculitis, it is more common in people with oily skin or those who wear tight clothing or heavy makeup that can clog pores and irritate the skin. Additionally, certain medical conditions such as diabetes, HIV/AIDS, and cancer can increase the risk of developing folliculitis.
Folliculitis is usually diagnosed through a physical examination and may require a biopsy to rule out other skin conditions. Treatment options for folliculitis depend on the severity and cause of the condition, but may include antibiotics, topical creams, or oral medications. It is important to seek medical attention if symptoms persist or worsen over time, as early treatment can help prevent complications and improve outcomes.
Pseudomonas aeruginosa
Pseudomonas aeruginosa hol holin family
Cyclic di-GMP-I riboswitch
RpoS
Biosurfactant
Pseudolysin
Occupational hazards in dentistry
Treatment of infections after exposure to ionizing radiation
Carbapenem-resistant enterobacteriaceae
Roberto Kolter
Panophthalmitis
Nitrite reductase (NO-forming)
Cefodizime
Arogenate dehydratase
ADP-ribosylation
Hydroxylamine reductase
Green nail syndrome
Nitrate reductase (NADH)
Green nails
Gluconate 2-dehydrogenase (acceptor)
Bacteriocin
Lipid A
S-methyl-5'-thioinosine phosphorylase
Biofilm
Isochorismate lyase
Kalai Mathee
Hypothiocyanite
Twitching motility
Monera
Sepsis
Emily Parker
Febrile neutropenia
RK2 plasmid
Tej P. Singh
Colonial morphology
Acetylornithine transaminase
Candida keroseneae
Fuel polishing
Aspiration pneumonia
Dracaena mannii
Antimicrobial
Guanidinopropionase
Pseudomonas sRNA P16
Contamination control
2,5-Diketopiperazine
Cefpirome
Arbonne International
Environmental DNA
Hospital-acquired infection
Opportunistic infection
Peptidoglycan recognition protein 3
Center for Biofilm Engineering
Carnitine 3-dehydrogenase
Betaine-aldehyde dehydrogenase
Peperomia pellucida
Hepcidin
Azlocillin
UDP-N-acetyl-2-amino-2-deoxyglucuronate dehydrogenase
ELOM-080
Pseudomonas aeruginosa Infection | HAI | CDC
Pseudomonas aeruginosa Infections: Practice Essentials, Background, Pathophysiology
Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients
Overview: A0K RS02315, Pseudomonas aeruginosa PACS2
Health Alert Network (HAN) - 00485 | Outbreak of Extensively Drug-resistant Pseudomonas aeruginosa Associated with Artificial...
Pseudomonas aeruginosa, Staphylococcus aureus, and Fluoroquinolone Use - Volume 11, Number 8-August 2005 - Emerging Infectious...
Molecules | Free Full-Text | Design and Synthesis of Lactams Derived from Mucochloric and Mucobromic Acids as Pseudomonas...
AID 164234 - Minimum bactericidal concentration against Pseudomonas aeruginosa; value ranges from 2-4 ug cm-3 - PubChem
Persistent pseudomonas aeruginosa infection in a child with cystic fibrosis - how to manage? | Pediatric Oncall Journal
Potency of Two Ear Cleansers In vitro Against Staphylococcus Intermedius, Pseudomonas Aeruginosa and Malassezia Pachydermatis -...
Health Alert Network (HAN) - 00485 | Outbreak of Extensively Drug-resistant Pseudomonas aeruginosa Associated with Artificial...
Association between mucosal barrier disruption by Pseudomonas aeruginosa exoproteins and asthma in patients with chronic...
Всемирная организация здравоохранения. Руководство по профилактике и борьбе с карбапенем-резистентными Enterobacteriaceae,...
Long term safety of inhaled tobramycin to treat Pseudomonas Aeruginosa infection in people With CF | European Cystic Fibrosis...
WHO EMRO | Prevalence and antibiotic resistance of Pseudomonas aeruginosa isolated from swimming pools in northern Greece |...
The interplay between Pseudomonas aeruginosa and human macrophages and neutrophils - Nottingham ePrints
Factors affecting catalase expression in pseudomonas aeruginosa biofilms and planktonic cells
The opportunistic pathogen Pseudomonas aeruginosa activates the DNA double-strand break signaling and repair pathway in...
Pseudomonas aeruginosa: A model for biofilm formation
Pseudomonas Aeruginosa Gene Expression
mntH1 protein (Pseudomonas aeruginosa) - STRING interaction network
A Pseudomonas aeruginosa small RNA regulates chronic and acute infection. | Nature;618(7964): 358-364, 2023 Jun. | MEDLINE
Mutations in respiratory complex I promote antibiotic persistence through alterations in intracellular acidity and protein...
CLEC5A is critical in Pseudomonas aeruginosa-induced NET formation and acute lung injury
View of Occurrence of blaKPC gene in clinical isolates of Pseudomonas aeruginosa from Brazil
4-Hidroksibenzoik Asit'in Pseudomonas Aeruginosa Biyofilmi Üzerine Etkisinin Araştırılması | GCRIS Database | Izmir Institute...
Membrane lipid renovation in Pseudomonas aeruginosa ‐ implications for phage therapy? - WRAP: Warwick Research Archive Portal
Effect of Lactobacillus fermentum filtrate on Pseudomonas aeruginosa adhesion at biotic and abiotic surfaces | Abstract
Opportunistic11
- Pseudomonas aeruginosa (PA) is an opportunistic pathogen that can cause infections in patients with compromised immunity including patients with neutropenia, HIV infection, burns, cancer, organ transplant surgery or in intensive care as well as Cystic Fibrosis (CF) patients. (nottingham.ac.uk)
- ABSTRACT Pseudomonas aeruginosa is an important agent of opportunistic infection in aquatic environments. (who.int)
- P. aeruginosa is an important agent of opportunistic infection in patients, particularly in those with respiratory complications and burns. (who.int)
- The opportunistic pathogen Pseudomonas aeruginosa activates the DNA double-strand break signaling and repair pathway in infected cells. (inserm.fr)
- We have investigated the genotoxic potential of Pseudomonas aeruginosa, an opportunistic pathogen causing devastating nosocomial infections in cystic fibrosis or immunocompromised patients. (inserm.fr)
- P. aeruginosa is an opportunistic pathogen. (nih.gov)
- And under normal circumstances, we don't get infections with opportunistic pathogens," said Fleiszig, who also studies the eye's defense mechanisms along with factors that enable P. aeruginosa to evade them. (nih.gov)
- Here, by directly examining bacterial gene expression in human -derived samples, we discover a gene that orchestrates the transition between chronic and acute infection in the opportunistic pathogen Pseudomonas aeruginosa . (bvsalud.org)
- Pseudomonas aeruginosa is a Gram-negative opportunistic pathogen which is a serious source of various hospital acquired diseases. (sysrevpharm.org)
- P. aeruginosa is an opportunistic pathogen with well-documented biofilm phenotypes that are distinct from its planktonic phenotypes. (nih.gov)
- Pseudomonas aeruginosa is an opportunistic pathogen often causing nosocomial infections that are resilient to treatment due to an extensive repertoire of intrinsic and acquired resistance mechanisms. (who.int)
Infections21
- Of the many different types of Pseudomonas , the one that most often causes infections in humans is called Pseudomonas aeruginosa , which can cause infections in the blood, lungs (pneumonia), or other parts of the body after surgery. (cdc.gov)
- In 2017, multidrug-resistant Pseudomonas aeruginosa caused an estimated 32,600 infections among hospitalized patients and 2,700 estimated deaths in the United States [ Source: 2019 AR Threats Report ]. (cdc.gov)
- Pseudomonas aeruginosa infections are generally treated with antibiotics. (cdc.gov)
- Unfortunately, in people exposed to healthcare settings like hospitals or nursing homes, Pseudomonas aeruginosa infections are becoming more difficult to treat because of increasing antibiotic resistance. (cdc.gov)
- CDC tracks Pseudomonas aeruginosa and the infections this germ can cause, including antibiotic-resistant infections. (cdc.gov)
- Learn more about how CDC's Antibiotic Resistance Laboratory Network detects highly resistant Pseudomonas aeruginosa infections. (cdc.gov)
- Bacterial infections, particularly hospital-acquired infections caused by Pseudomonas aeruginosa , have become a global threat with a high mortality rate. (mdpi.com)
- The common presentations are meconium ileum in neonates, recurrent lower respiratory tract infections (Pseudomonas spp pneumonia, bronchiectasis), steatorrhoea, azoospermia, and in late stages hepatobiliary and endocrine pancreatic dysfunctions. (pediatriconcall.com)
- Pseudomonas aeruginosa infections and biofilms have been implicated in recalcitrant CRS. (physiciansweekly.com)
- The carbohydrate-binding protein LecA (PA-IL) from Pseudomonas aeruginosa plays an important role in the formation of biofilms in chronic infections. (fu-berlin.de)
- P. aeruginosa is also a human pathogen that causes infection in burn patients, and is the predominant cause of lung infections and mortality in patients with cystic fibrosis (CF) [14,15]. (edu.au)
- That's the story behind this image showing an intricate colony of millions of the single-celled bacterium Pseudomonas aeruginosa , a common culprit in the more than 700,000 hospital-acquired infections estimated to occur annually in the United States. (nih.gov)
- Questions remain about artificial tears linked to an outbreak of Pseudomonas aeruginosa infections involving 68 people in 16 states, including 8 cases of vision loss, as well as lung and urinary tract infections, and one death. (nih.gov)
- In studies funded by the NEI, Fleiszig uses P. aeruginosa as a model pathogenic organism to better understand the pathogenesis of bacterial eye infections. (nih.gov)
- The expression level of this gene , here named sicX, is the highest of the P. aeruginosa genes expressed in human chronic wound and cystic fibrosis infections , but it is expressed at extremely low levels during standard laboratory growth . (bvsalud.org)
- P. aeruginosa bacteria can cause mild illness in healthy people, such as ear infections and skin rashes after exposure to inadequately cleaned hot tubs or pools. (nih.gov)
- However, serious P. aeruginosa -associated bloodstream infections and pneumonia can occur in hospitalized patients with weakened immune systems, including people who have wounds from surgery or are using breathing machines or catheters. (nih.gov)
- Pseudomonas aeruginosa is one of the most common nosocomial infections worldwide, and it frequently causes ventilator-associated acute pneumonia in immunocompromised patients. (sinica.edu.tw)
- Consideration of such effects needs to be urgently prioritised in order to develop the most effective phage therapy strategies for P. aeruginosa infections. (warwick.ac.uk)
- Pseudomonas aeruginosa has been implicated in several nosocomial infections , where it has caused grave complications in immunocompromised patients . (bvsalud.org)
- For more information, please go to Enterobacter Infections , Urinary Tract Infection (UTI) and Cystitis (Bladder Infection) in Females , Urinary Tract Infection in Males , Pseudomonas aeruginosa Infections , and Acinetobacter . (medscape.com)
Isolates7
- Epi-Otic killed all 5 of the Pseudomonas isolates within 1 minute, both undiluted and at 1/5 dilution. (vin.com)
- Exoproteins from 40 P. aeruginosa isolates were collected in planktonic and biofilm form and applied to air-liquid interface (ALI) cultures of primary human nasal epithelial cells (HNECs). (physiciansweekly.com)
- Exoproteins from planktonic P. aeruginosa clinical isolates from asthmatic CRS patients have detrimental effects on the mucosal barrier and induce IL-6 production potentially contributing to the mucosal inflammation in CRS patients. (physiciansweekly.com)
- Compared with other studies, the prevalence of P. aeruginosa in swimming pools was relatively low, while the antibiotic resistance pattern of these community isolates was not high. (who.int)
- In this work, we apply genomic sequencing to 9 serially-collected P. aeruginosa isolates cultured during the course of an acute systemic infection in a single patient in which both a hypermutator phenotype and ceftazidime-avibactam (CZA) resistance rapidly emerged in vivo. (nih.gov)
- We sequenced the whole genomes of 176 P. aeruginosa isolates collected in 2013-2014 by the Antimicrobial Resistance Surveillance Program. (who.int)
- Pseudomonas aeruginosa isolates from this sample site showed the highest (100%) resistance to cephalosporins ( cefuroxime ) and nitrofurantoin . (bvsalud.org)
Infection15
- Pseudomonas aeruginosa has become an important cause of gram-negative infection, especially in patients with compromised host defense mechanisms. (medscape.com)
- Desai L, Shah I. Persistent Pseudomonas Aeruginosa Infection in a child with Cystic Fibrosis - How to manage? (pediatriconcall.com)
- When used as a treatment for long term (chronic) Pseudomonas lung infection, tobramycin inhalation powder used twice a day, on a month on-month off basis over 1 year, continues to appear effective and safe. (ecfs.eu)
- Previous studies have shown it to have similar effectiveness to nebulised tobramycin solution for inhalation for people with chronic Pseudomonas lung infection. (ecfs.eu)
- Our data revealed that infection of immune or epithelial cells by P. aeruginosa triggered DNA strand breaks and phosphorylation of histone H2AX (γH2AX), a marker of DNA double-strand breaks. (inserm.fr)
- Together, these data show for the first time that infection by P. aeruginosa activates the DNA double-strand break repair machinery of the host cells. (inserm.fr)
- This novel information sheds new light on the consequences of P. aeruginosa infection in mammalian cells. (inserm.fr)
- However, the role of P. aeruginosa hypermution in the acute systemic infection remains unclear. (nih.gov)
- 1] Mucin glycans attenuate the virulence of Pseudomonas aeruginosa in infection . (nih.gov)
- While infection with the specific, highly resistant bacterial strain at the heart of the outbreak is rare, P. aeruginosa as a bacterial species is everywhere. (nih.gov)
- A Pseudomonas aeruginosa small RNA regulates chronic and acute infection. (bvsalud.org)
- Deletion of sicX causes P. aeruginosa to switch from a chronic to an acute lifestyle in multiple mammalian models of infection . (bvsalud.org)
- P. aeruginosa undergoes changes in membrane lipids when it encounters phosphorus stress, an environmental perturbation that is likely to occur during infection. (warwick.ac.uk)
- To investigate the efficacy and safety of 4 antipseudomonal treatments in children with cystic fibrosis with recently acquired Pseudomonas aeruginosa infection. (nih.gov)
- The primary cause of death in individuals with CF is progressive obstructive pulmonary disease associated with chronic Pseudomonas aeruginosa (PA) infection. (nih.gov)
Biofilms9
- Previous work with Pseudomonas aeruginosa showed that catalase activity in biofilms was significantly reduced relative to that in planktonic cells. (montana.edu)
- Pseudomonas aeruginosa has become a model organism for the study of biofilms due to its metabolic versatility and variability in its response to environmental signals, which promotes successful colonization of different habitats and growth under varying environmental conditions [12,13]. (edu.au)
- 2] Mucins trigger dispersal of Pseudomonas aeruginosa biofilms . (nih.gov)
- The functioning of the EPS matrix in holding cells of Pseudomonas aeruginosa together and forming the mature biofilms. (ukessays.com)
- The exopolysaccharide genes such as pilB, pslA, lecA, ureB and alginate genes are responsible for the formation of pseudomonas biofilms. (ukessays.com)
- The microcarriers made up of dextrons in the range of 60-90µm in size are used as a surface for Pseudomonas aeruginosa to form biofilms. (ukessays.com)
- Reverse diauxie has been described in planktonic cultures, but it has not been documented explicitly in P. aeruginosa biofilms. (nih.gov)
- Label-free proteomics identified dozens of proteins associated with biofilm formation including 16 that have not been previously reported, highlighting both the advantages of the methodology utilized here and the complexity of the proteomic adaptation for P. aeruginosa biofilms. (nih.gov)
- Documenting the reverse diauxic phenotype in P. aeruginosa biofilms is foundational for understanding cellular nutrient and energy fluxes, which ultimately control growth and virulence. (nih.gov)
Multidrug-resistant2
- For some multidrug-resistant types of Pseudomonas aeruginosa , treatment options might be limited. (cdc.gov)
- Doctors found that he had multidrug-resistant Pseudomonas aeruginosa keratitis . (naturalnews.com)
Bacteria5
- Pseudomonas is a type of bacteria (germ) that is found commonly in the environment, like in soil and in water. (cdc.gov)
- Gram-negative bacteria including P. aeruginosa employ N -acyl homoserine lactones (AHLs) as chemical signals to regulate the expression of pathogenic phenotypes through a mechanism called quorum sensing (QS). (mdpi.com)
- Pseudomonas aeruginosa is the gram negative rod shaped bacteria is found in all natural and man made environments. (ukessays.com)
- Pseudomonas aeruginosa is a member of gamma proteobacteria class of bacteria. (ukessays.com)
- Current study aimed to determination of inhibition ability of the probiotic bacteria (Lactobacillus fermentum) to inhibit P. aeruginosa adhesion. (sysrevpharm.org)
Cystic fibrosis patients2
- 5) Pseudomonas aeruginosa colonization is highly prevalent in the lungs of cystic fibrosis patients and leads to progressive pulmonary function decline and its eradication is particularly challenging. (pediatriconcall.com)
- P. aeruginosa hypermutators have been frequently in cystic fibrosis patients, where they can facilitate the evolution of antimicrobial resistance. (nih.gov)
Acinetobacter1
- Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter species and extra-intestinal pathogenic Escherichia coli . (nih.gov)
Antibiotics3
- Some strains of P. aeruginosa are resistant to most or all antibiotics, including aminoglycosides, cephalosporins, fluoroquinolones and carbapenems. (nih.gov)
- Pseudomonas aeruginosa is an important Gram-negative pathogen with intrinsic resistance to many clinically used antibiotics. (warwick.ac.uk)
- The primary end points were time to pulmonary exacerbation requiring intravenous antibiotics and proportion of P aeruginosa -positive cultures. (nih.gov)
Resistant5
- The percentages of fluoroquinolone-resistant Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus (MRSA) were obtained from yearly antibiograms at each hospital. (cdc.gov)
- A number of case-control studies at individual hospitals have identified fluoroquinolone use as a risk factor for acquisition of fluoroquinolone-resistant P. aeruginosa and methicillin-resistant S. aureus (MRSA) ( 4 - 8 ). (cdc.gov)
- We measured fluoroquinolone use as well as the percentages of MRSA and fluoroquinolone-resistant P. aeruginosa across 24 US hospitals during a 5-year period. (cdc.gov)
- In December 2013, the P. aeruginosa was resistant to tobramycin and she was treated with oral ciprofloxacin and nebulized Colistin for 6 weeks. (pediatriconcall.com)
- Compared with a nutrient-rich lab broth, saline or even plain water provide P. aeruginosa with an environment where it tends to become even more virulent and drug-resistant because it's adapting as a response to stress. (nih.gov)
Pneumonia1
- Thus, CLEC5A is a promising therapeutic target to reduce ventilator-associated lung injury and fibrosis in P. aeruginosa-induced pneumonia. (sinica.edu.tw)
Chronic2
- Association between mucosal barrier disruption by Pseudomonas aeruginosa exoproteins and asthma in patients with chronic rhinosinusitis. (physiciansweekly.com)
- This work solves a decades-old question regarding the molecular basis underlying the chronic-to-acute switch in P. aeruginosa and suggests oxygen as a primary environmental driver of acute lethality. (bvsalud.org)
Swarming motility1
- Using \textit{Pseudomonas aeruginosa} as a model organism, we investigate physical factors that either facilitate or restrict the swarming motility. (aps.org)
Strain1
- As of March 14, 68 individuals from 16 states have been infected with a rare strain of Pseudomonas aeruginosa , reported the Centers for Disease Control and Prevention (CDC). (naturalnews.com)
Prevalence2
- No difference in the rate of exacerbation or prevalence of P aeruginosa positivity was detected between cycled and culture-based therapies. (nih.gov)
- This is the first study to report the prevalence of MDR P. aeruginosa isolated from residential sewage in Dutsin-Ma, Katsina State , Nigeria . (bvsalud.org)
20181
- She continued to have recurrent pneumonias due to P. aeruginosa for which she was on nebulized Colistin and finally succumbed to her disease in February 2018. (pediatriconcall.com)
Sputum2
- Her sputum cultures subsequently grew Bukholderia cepacia, Streptococcus pneumoniae, Klebsiella pneumoniae and Pseudomonas aeruginosa over the next few months. (pediatriconcall.com)
- Her sputum cultures continued to grow Pseudomonas aeruginosa on and off. (pediatriconcall.com)
Activates1
- P. aeruginosa activates CLEC5A to induce caspase-1-dependent NET formation, but it neither causes gasdermin D (GSDMD) cleavage nor contributes to P. aeruginosa-induced neutrophil death. (sinica.edu.tw)
Antimicrobial resistance1
- Our aim was to evaluate the occurrence and antimicrobial resistance of P. aeruginosa in the water of swimming pools in northern Greece. (who.int)
Phage therapy1
- Membrane lipid renovation in Pseudomonas aeruginosa ‐ implications for phage therapy? (warwick.ac.uk)
Gram-negative1
- Pseudomonas aeruginosa belongs to a vast genus of obligate aerobic, non-fermenting, saprophytic, Gram-negative bacilli widespread in nature, particularly in moist environments such as water, sewage, soil, plants and animals [1]. (who.int)
Genomes2
- Enhanced annotations and features for comparing thousands of Pseudomonas genomes in the Pseudomonas genome database. (pseudomonas.com)
- The population of P. aeruginosa in the Philippines was diverse, with clonal expansions of XDR genomes belonging to multi-locus sequence types ST235, ST244, ST309, and ST773. (who.int)
Bacterial species1
- Most bacterial species, including \textit{P. aeruginosa}, synthesize bio-surfactants to aid in swarming. (aps.org)
Patients2
- Staphylococcus aureus and Haemophilus Influenzae colonization is common during early childhood but ultimately Pseudomonas aeruginosa is isolated from CF patients due to impaired clearance directly induced by a defective CFTR gene. (pediatriconcall.com)
- The aim is to determine the effect of P. aeruginosa exoproteins isolated from CF and non-CF CRS patients on the mucosal barrier. (physiciansweekly.com)
Gene2
- Gene deletion, mutagenesis, and complementation in P. aeruginosa identified ExoS bacterial toxin as the major factor involved in γH2AX induction. (inserm.fr)
- This was further supported by long-read sequencing of one representative XDR isolate, which revealed the presence of an integron carrying multiple resistance genes, including bla VIM-2 , with differences in gene composition and synteny to other P. aeruginosa class 1 integrons described before. (who.int)
Cultures2
- P. aeruginosa biofilm cultures preferentially consumed lactic acid over glucose, and in addition, the cultures catabolized the substrates completely and did not exhibit the acetate secreting "overflow" metabolism that is typical of many model microorganisms. (nih.gov)
- Participants randomized to cycled therapy received tobramycin inhalation solution (300 mg twice a day) for 28 days, with oral ciprofloxacin (15-20 mg/kg twice a day) or oral placebo for 14 days every quarter, while participants randomized to culture-based therapy received the same treatments only during quarters with positive P aeruginosa cultures. (nih.gov)
Occurrence1
- The occurrence of MDR P. aeruginosa from a residential sewage site that may contaminate drinking water sources in the study area is of public health threat to the inhabitants. (bvsalud.org)
Resistance3
- Univariate linear regression showed significant associations between a hospital's volume of fluoroquinolone use and percent resistance in most individual study years (1999-2001 for P. aeruginosa , 1999-2002 for S. aureus ). (cdc.gov)
- Ecologic investigations across multiple hospitals have reported significant correlations between fluoroquinolone use and percent resistance for MRSA ( 9 ) and P. aeruginosa ( 10 , 11 ). (cdc.gov)
- The potent activity of Epi-Otic against Pseudomonas is also of special interest in view of the increasing resistance shown by this genus against antimicrobials that may be used following cleansing agents in the therapy of otitis externa. (vin.com)
Grown2
- In this image, the Pseudomonas biofilm has grown in a laboratory dish to about the size of a dime. (nih.gov)
- Planktonically grown Pseudomonas aeruginosa is known to prioritize the consumption of organic acids including lactic acid over catabolism of glucose using a CCR strategy termed "reverse diauxie. (nih.gov)
Lung3
- While pattern recognition receptors (PRRs) TLR4 and TLR5 are required for host defense against P. aeruginosa invasion, the PRR responsible for P. aeruginosa-induced NET formation, proinflammatory cytokine release, and acute lung injury remains unclear. (sinica.edu.tw)
- We found that myeloid C-type lectin domain family 5 member A (CLEC5A) interacts with LPS of P. aeruginosa and is responsible for P. aeruginosa-induced NET formation and lung inflammation. (sinica.edu.tw)
- Blockade of CLEC5A attenuates P. aeruginosa-induced NETosis and lung injury, and simultaneous administration of anti-CLEC5A mAb with ciprofloxacin increases survival rate and decreases collagen deposition in the lungs of mice challenged with a lethal dose of P. aeruginosa. (sinica.edu.tw)
Healthcare3
- Pseudomonas aeruginosa lives in the environment and can be spread to people in healthcare settings when they are exposed to water or soil that is contaminated with these germs. (cdc.gov)
- Healthcare facilities should have water management plans (see Reduce Risk from Water ) that help ensure water quality and reduce the risk of exposure to potentially harmful germs like Pseudomonas aeruginosa . (cdc.gov)
- The recalled eye drops were manufactured by Global Pharma Healthcare in India, where P. aeruginosa is often associated with hospital outbreaks. (naturalnews.com)
Harmful1
- The researchers found that in the presence of glycans, P. aeruginosa was rendered less harmful and infectious. (nih.gov)
Study1
- In their new study, published in Nature Microbiology , Ribbeck, lead author Kelsey Wheeler, and their colleagues studied mucus and its interactions with Pseudomonas aeruginosa . (nih.gov)
Surface1
- Generally the twitching motility of the P.aeruginosa helps to use its unipolar flagellum to adhere a surface. (ukessays.com)